Two of Climb Bio’s most promising therapies—CLYM116 and budoprutug—will be in the spotlight at the European Renal Association Congress 2026. The company is sharing early safety data and a Phase 2 trial update in Glasgow, Scotland, detailing its mission to advance treatment options for immune-mediated kidney diseases.
Subscribe
Biotechnology
Chronic Illness Management
Therapy Options
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
Photo by Benzinga
Key Takeaways:
- Climb Bio will present at the European Renal Association Congress 2026 in Glasgow, Scotland.
- CLYM116, a “sweeper” anti-APRIL monoclonal antibody, is being evaluated for IgA nephropathy.
- Phase 1 safety data on CLYM116 will be revealed during the congress.
- Budoprutug, an anti-CD19 monoclonal antibody, is in a Phase 2 trial for primary membranous nephropathy.
- Both therapies aim to address immune-mediated kidney diseases through innovative approaches.
Climb Bio Unveils Novel Kidney Disease Therapies
Climb Bio, Inc. is heading to the European Renal Association Congress 2026, set to take place from June 3–6 in Glasgow, Scotland. There, the company will share the latest developments for two of its monoclonal antibody programs—CLYM116 and budoprutug—offering insights into the future of immune-mediated kidney disease treatments.
The CLYM116 Approach
CLYM116 is described as a novel “sweeper” anti-APRIL monoclonal antibody developed to tackle IgA nephropathy (IgAN). The upcoming presentation will focus on pharmacokinetic and pharmacodynamic modeling, drawing on data gathered from nonhuman primates and human subjects. Early results from an ongoing Phase 1 study in healthy volunteers will also be showcased, providing a first look at the therapy’s safety profile.
Budoprutug’s Phase 2 Study
In parallel, Climb Bio is conducting a Phase 2 study called PrisMN to evaluate budoprutug—an anti-CD19 monoclonal antibody with enhanced effector functions—for patients with primary membranous nephropathy (pMN). As part of a “trial-in-progress” poster, the company will present the study’s objectives, design, and goals. This program aims to address broader B-cell mediated diseases, signaling Climb Bio’s commitment to developing innovative treatments for various immune-driven conditions.
A Closer Look at Climb Bio
Based in Wellesley Hills, Massachusetts, Climb Bio is a clinical-stage biotechnology firm focused on delivering disease-modifying medicines for patients facing immune-mediated diseases. Its pipeline targets kidney health, with budoprutug and CLYM116 at the forefront. With both therapies showing promise for serious renal conditions, Climb Bio’s presence at the ERA Congress underscores its potential impact on the future of immunotherapy.
Previewing the ERA 2026 Agenda
Key sessions include Climb Bio’s focused oral presentation of CLYM116 data on June 5, 2026, at 15:03–15:09 BST, and poster viewing of the budoprutug Phase 2 study throughout June 4–5. The congress, renowned for bringing together global experts in nephrology, offers a significant platform for Climb Bio to share pivotal data with the scientific community.
